<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03637205</url>
  </required_header>
  <id_info>
    <org_study_id>HRC[045584]</org_study_id>
    <nct_id>NCT03637205</nct_id>
  </id_info>
  <brief_title>Extracorporeal Life Support in Cardiogenic Shock</brief_title>
  <acronym>ECLS-SHOCK</acronym>
  <official_title>Prospective Randomized Multicenter Study Comparing Extracorporeal Life Support Plus Optimal Medical Care Versus Optimal Medical Care Alone in Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock Undergoing Revascularization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leipzig Heart Institute GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heart Center Leipzig - University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IHF GmbH - Institut f√ºr Herzinfarktforschung</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Leipzig Heart Institute GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to examine whether treatment with extracorporeal life support (ECLS)
      in addition to revascularization with percutaneous coronary intervention (PCI) or
      alternatively coronary artery bypass grafting (CABG) and optimal medical treatment is
      beneficial in comparison to no ECLS in patients with severe infarctrelated cardiogenic shock
      with respect to 30-day mortality
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 20, 2019</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>30-day mortality</measure>
    <time_frame>30 days</time_frame>
    <description>30-day all-cause death after randomization according to the intention-to-treat principle</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to death within 6 and 12 months follow-up</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of mechanical ventilation</measure>
    <time_frame>0 to 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to hemodynamic stabilization</measure>
    <time_frame>0 to 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of catecholamine therapy</measure>
    <time_frame>0 to 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serial creatinine-level and creatinine-clearance</measure>
    <time_frame>0 to 10 days from time of randomization until stabilization</time_frame>
    <description>Creatinine-clearance (Cockcroft-Gault-Formula)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>0 to 11 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>0 to 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serial SAPS-II score</measure>
    <time_frame>0 to 11 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean and area under the curve of arterial lactate</measure>
    <time_frame>0 to 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute renal failure requiring renal replacement therapy</measure>
    <time_frame>0 to 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral performance category (CPC)</measure>
    <time_frame>30 days, 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization for heart failure</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent infarction</measure>
    <time_frame>30 days, 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Repeat revascularization (PCI or CABG)</measure>
    <time_frame>30 days, 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Status of Quality of life measured by EQ-5D-5L descriptive system</measure>
    <time_frame>12 months</time_frame>
    <description>The EQ-5D-5L descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems expressed by 1-digit-numbers ranging from 1 (extreme problems) to 5 (no problems). The toal score ranges from 0-15 where 15 is the worst score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Status of Quality of life measured by EQ VAS</measure>
    <time_frame>12 months</time_frame>
    <description>The EuroQol Group visual analogue scale (EQ VAS) records the patient's self-rated health on a vertical visual analogue scale from 0 to 100, where the maximum 100 is labelled 'The best health you can imagine' and the minimum 0 is labelled 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">420</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <condition>Cardiogenic Shock</condition>
  <arm_group>
    <arm_group_label>ECLS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PCI (or CABG) plus medical treatment + ECLS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No ECLS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PCI (or CABG) plus medical treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ECLS insertion</intervention_name>
    <description>After diagnostic angiography the culprit lesion should be identified and revascularization (preferably by PCI, alternatively CABG) should be planned. ECLS insertion should be performed preferably before revascularization</description>
    <arm_group_label>ECLS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Revascularisation and optimal medical treatment</intervention_name>
    <description>After diagnostic angiography the culprit lesion should be identified and revascularization (preferably by PCI, alternatively CABG) should be planned.</description>
    <arm_group_label>ECLS</arm_group_label>
    <arm_group_label>No ECLS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cardiogenic shock complicating AMI (STEMI or NSTEMI) plus obligatory:

          -  Planned revascularization (PCI or alternatively CABG)

          -  Systolic blood pressure &lt;90 mmHg &gt;30 min or catecholamines required to maintain
             pressure &gt;90 mmHg during Systole

          -  Signs of impaired organ perfusion with at least one of the following criteria a)
             Altered mental Status, b) Cold, clammy skin and extremities, c) Oliguria with urine
             output &lt;30 ml/h

          -  Arterial lactate &gt;3 mmol/l

          -  Informed consent

        Exclusion Criteria:

          -  Resuscitation &gt;45 minutes

          -  Mechanical cause of cardiogenic shock

          -  Onset of shock &gt;12 h

          -  Severe peripheral artery disease with impossibility to insert ECLS cannulae

          -  Age &lt;18 years or age &gt;75 years

          -  Shock of other cause (bradycardia, sepsis, hypovolemia, etc.)

          -  Other severe concomitant disease with limited life expectancy &lt;6 months

          -  Pregnancy

          -  Participation in another trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Holger Thiele, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director, Department of Cardiology, Heart Center Leipzig</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Holger Thiele, MD</last_name>
    <phone>+49 341 865 1428</phone>
    <email>holger.thiele@medizin.uni-leipzig.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Herzzentrum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holger Thiele, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>August 13, 2018</study_first_submitted>
  <study_first_submitted_qc>August 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2018</study_first_posted>
  <last_update_submitted>June 24, 2019</last_update_submitted>
  <last_update_submitted_qc>June 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Shock, Cardiogenic</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

